04.26.19
Bristol-Myers Squibb
1Q Revenues: $5.9 Billion (+14%)
1Q Earnings: $1.7 billion (+15%)
Comments: Eliquis sales were up 28% in the quarter to $1.9 billion. Opdivo sales were up 19% to $1.8 billion. Orencia sales were $640 million, up 8%. Yervoy sales were up 54% to $354 million. Baraclude sales were down 37% to $141 million. Other established brands sales were down 21% to $487 million. U.S. revenues increased 24% to $3.4 billion in the quarter. International revenues increased 2%. In April, the company announced plans to acquire Celgene Corporation, which is expected to close in the third quarter.
1Q Revenues: $5.9 Billion (+14%)
1Q Earnings: $1.7 billion (+15%)
Comments: Eliquis sales were up 28% in the quarter to $1.9 billion. Opdivo sales were up 19% to $1.8 billion. Orencia sales were $640 million, up 8%. Yervoy sales were up 54% to $354 million. Baraclude sales were down 37% to $141 million. Other established brands sales were down 21% to $487 million. U.S. revenues increased 24% to $3.4 billion in the quarter. International revenues increased 2%. In April, the company announced plans to acquire Celgene Corporation, which is expected to close in the third quarter.
